CACNA1C and Parkinson disease: For example, human Cav1.2 (hCav1.2) is one of the important targets of cardiovascular diseases, whereas human Cav1.3 (hCav1.3) is involved in the pathogenesis of Parkinson’s disease (PD) and is considered to be a therapeutic target for neurodegenerative diseases [13,14,15,16,17].